Impact on food & beverage In the food & beverage industry, the increasing use of GLP-1 agonists like Semaglutide could lead to a shift in consumer preferences
Risks include receiving counterfeit or contaminated products, incorrect dosing leading to adverse reactions, or no medication being delivered despite payment
However, it was not for yet another decade that it received approval by the FDA for the US market when two companies, Tercica and Insmed, released their respective products Increlex and Iplex in 2005
Batschelett, View ORCID ProfileNicolaas A.J
Retatrutide's triple-agonist design also targets resting energy expenditure
Feng LL, Bie SY, Deng ZH, Bai SM, Shi J, Qin CL, et al